Are Peptides Legal Again? What FDA's 2026 Compounding List Changes Mean for Sellers

The FDA's 2026 compounding list change gives your research use only store no new path to sell products for use by people. Several peptide names were moved to a withdrawn category on the list of bulk drug substances that may present significant safety risks, and that list affects only what certain pharmacies and outsourcing facilities can compound under 503A and 503B. Peptides are not broadly legal again in the way many founders hope: the update is a narrow administrative change, not a new approval or a change in enforcement policy for unapproved peptides sold outside of regulated compounding.

Key Facts

The law still prohibits selling a product with the intent that it be used as a drug. That intent can be shown by the circumstances of the sale, including what the seller knows about how buyers will use the product. Keep your product pages and support replies on research use only facts.

What FDA Changed on Its Compounding Pages

The FDA maintains a page titled "Certain Bulk Drug Substances that May Present Significant Safety Risks" FDA: Safety Risks page. In 2026, the agency updated that page to show that several substances were withdrawn by their nominators. The withdrawn list includes AOD-9604, BPC-157, CJC-1295, Epitalon, Selank, Semax, Thymosin alpha 1, and Thymosin Beta-4 Fragment, among other substances. The page states these substances were previously in category 2 of the interim policies. The update means the FDA is no longer actively evaluating these specific substances for inclusion on a list that would restrict their use in compounding.

In this context, this change is administrative. The nominators who originally asked the FDA to evaluate these substances for compounding decided to pull their nominations. The FDA's action simply reflects that withdrawal. The agency did not issue a new approval, a safety finding, or a policy statement about the legality of selling these peptides outside of a compounding pharmacy.

How the Category 2 Withdrawal Works

Category 2 is a label the FDA used during its interim policy for bulk drug substances nominated for compounding. A substance placed in category 2 was one that had been nominated but for which the FDA had not received enough evidence to support a safety evaluation for compounding FDA: Bulk Drug Substances page. The agency's framework divided substances into categories to prioritize review. A withdrawal from category 2 means the nominator stopped pursuing the evaluation. The substance is removed from the active review queue.

A withdrawal from category 2 is not an FDA approval. The agency's page does not state that these substances are now safe, effective, or legal to compound. The withdrawal simply ends that specific evaluation process. For a research use only seller, this change does not alter the legal requirement that a product cannot be sold with the intent that it be used for human therapeutic purposes. The FDA's compounding lists govern what registered pharmacies and outsourcing facilities may do, not what a research use only business may sell.

What 503A and 503B Compounding Mean

The FDA's compounding policies are built on two sections of the Federal Food, Drug, and Cosmetic Act: 503A and 503B. Section 503A applies to traditional pharmacy compounding. Section 503B applies to outsourcing facilities that can compound larger batches without individual prescriptions FDA: Compounding Laws and Policies. The bulk drug substance lists the FDA publishes, including the safety risks page, are used to determine what substances these entities can and cannot use in their compounding operations.

In this context, these lists do not create a general permission structure for all sellers. A business that sells peptides labeled "for research use only" and not as a compounded drug is operating outside the 503A and 503B framework. The FDA's update to the withdrawn list does not bring research use only peptides into the compounding framework. The law still defines a drug partly by its intended use, and selling a substance with the knowledge that buyers will use it as a drug can establish that intent 21 CFR 201.128.

The Pharmacy Compounding Advisory Committee Role

The Pharmacy Compounding Advisory Committee (PCAC) is the body that reviews nominated bulk drug substances and makes recommendations to the FDA FDA: PCAC page. The committee evaluates safety data, clinical need, and other factors for substances proposed for compounding. When a nominator withdraws a substance, the PCAC review process for that substance stops. The committee does not issue a final recommendation on a withdrawn substance.

The PCAC's work is limited to the compounding context. Its recommendations do not address the legality of selling peptides as research chemicals, reference materials, or for any other non-compounding purpose. A research use only seller's obligations are not defined by PCAC proceedings. The seller's obligations come from the general drug and misbranding provisions of the FD&C Act.

What the Change Does Not Cover

The FDA's update does not cover research use only resale. The agency's compounding pages address pharmacies and outsourcing facilities. A research use only seller is not a compounding pharmacy. The product pages and support replies for a research use only business stay on facts like the product name, lot number, and purity. The business does not describe preparing, mixing, giving, or using a product. The business does not state or imply that a product changes anything about a body.

The FDA's action also does not preempt state law. States can have their own restrictions on peptides. A seller must check the rules in each state where it operates. The federal update on a compounding list does not override state-level prohibitions or licensing requirements.

Comparison: Category 2 Status Before and After Withdrawal

Comparison: 503A Pharmacy vs. 503B Outsourcing Facility

Common Mistakes to Avoid

Mistaking a Withdrawal for an Approval

A withdrawal from category 2 is not an FDA approval. The agency's page does not state that the withdrawn substances are safe or effective. A seller who markets a product by pointing to this update as proof of legality is making a claim the source does not support FDA: Safety Risks page.

Assuming the Change Applies to All Sales Channels

The FDA's compounding lists apply to pharmacies and outsourcing facilities under sections 503A and 503B. A research use only seller is not in that category. The update does not create a new exemption for direct-to-consumer sales of peptides FDA: Compounding Laws and Policies.

Ignoring the Intent Standard

A product's regulatory status depends on its intended use. The law states that intent can be shown by the circumstances surrounding the sale, including what the seller knows about how buyers will use the product 21 CFR 201.128. A research use only label alone does not eliminate risk if other facts show an intent for human use.

How to Read a Bulk Drug Substance List Entry

Each entry on the FDA bulk drug substance lists has a fixed set of fields. You will see the substance name, the category number, and the date of the last review. Some entries also show a Federal Register citation. The category number tells you if the substance can be used in compounding right now. A category 1 listing means the substance may be eligible. A category 2 listing means it is under review or has safety concerns. A category 3 listing means it is not allowed for compounding.

You must also check the notes column on the list. The notes often add limits that the category number alone does not show. For example, a note might restrict use to a certain route or a certain strength. If you skip the notes, you can miss a key limit. Always read the full row before you make a sourcing choice. The official list is on the FDA site under the compounding section.

Check the effective date on every entry

Each list update has a clear effective date printed at the top of the page. The date tells you when the new status starts. If you act before that date, you follow the old list. If you act on or after that date, you follow the new list. A substance can move from category 2 to category 1 on a set day. You must track that day for your stock orders.

The effective date also matters for your paperwork. Your batch records should show which list version you used when you sourced a substance. An inspector may ask to see that link. Keep a saved copy of the list page from the day you placed the order. A simple screen print with the date in the file name works well. This small step can save you from a big dispute later.

Watch for the Federal Register notice link

Many list changes start with a notice in the Federal Register. The list entry often links to that notice. The notice gives the full back story for the change. It explains the data the FDA looked at and the public comments they got. Reading the notice helps you grasp why a substance moved. That context can guide your own risk check.

The notice also tells you if the change is final or still open for comment. An open comment period means the rule could shift again soon. You should not build a long term plan on a status that is still in play. Bookmark the notice and set a reminder for the comment close date. Then check the final rule when it posts. This keeps your business steps in line with the last word from the agency.

State Board Rules Versus Federal Compounding Lists

Your state board of pharmacy sets rules that run side by side with federal law. A substance that is allowed on the federal list may still be blocked by your state. State boards can adopt the federal lists in full, in part, or not at all. Some states keep their own list of allowed bulk substances. Others add extra record keeping rules. You must check both layers before you ship to a state.

State inspectors look at your compliance with state law first. They can cite you even if you followed the federal list to the letter. The penalty can range from a fine to a license hold. Before you add a new peptide to your catalog, call your state board or visit their site. Ask if they have a written policy on the substance. Get the answer in writing if you can. This paper trail shows you did your homework.

Find your state board's compounding policy page

Most state boards post their compounding rules on a public web page. Look for a tab called laws, rules, or guidance. The page may list adopted USP chapters or a state specific formulary. Some boards publish a simple yes or no list for bulk substances. If the page is not clear, send a short email to the board's compliance officer. Keep your question narrow and fact based.

Do not assume that a lack of state action means a green light. Silence from the board is not the same as approval. A board may simply not have reviewed the substance yet. In that case, you carry the risk. Talk to a health care attorney in your state for a formal view. The cost of that talk is far less than the cost of a board action against your license.

Track state rule updates on a set schedule

State rules change on a cycle that you can map out. Many boards update their rules once or twice a year. Put a recurring task on your calendar to check each state where you ship. Look for new proposed rules, new final rules, and new guidance documents. Sign up for the board's email list if they offer one. A small change in a state definition can shift what you can sell there.

When a state rule changes, update your internal shipping map right away. Your order system should block sales to states where a substance is not allowed. Train your support team on the new map so they can answer buyer questions. A quick, clear answer builds trust. A wrong answer can lead to a complaint to the board. Stay ahead of the cycle and you stay out of trouble.

Documenting Your Due Diligence on a Substance

You need a paper trail that shows why you chose to list a substance. This trail is your due diligence file. It should include the current FDA list entry, the Federal Register notice, and any state board letters. Add your own check of the safety data that is public. The file proves you did not ignore a known risk. If an inspector asks, you can hand over the file in one neat stack.

Your file should also note the date you checked each source. A check from two years ago does not help you today. Set a rule to refresh the file every six months or when the FDA list changes, whichever comes first. Write a short note each time you refresh it. The note should say what you looked at and what, if anything, changed. This habit turns a vague duty into a clear, repeatable task.

Build a one page substance check sheet

Make a simple form that you fill out for each new substance. The form should have fields for the FDA category, the effective date, and the state status. Add a field for the safety data sources you reviewed. Leave a space for your final call and your signature. A one page sheet keeps the task light and fast. You are more likely to do a task that feels quick.

Store the sheet in a cloud folder sorted by substance name. Name each file with the substance and the date, like "SubstanceX_2026_03_15.pdf". This makes it easy to find the right file during an audit. If you ever need to show a pattern of care, you can pull a full set in seconds. The goal is to make your diligence visible and easy to grasp for an outsider.

Keep a log of adverse event reports you review

Public databases like the FDA Adverse Event Reporting System hold reports you should scan. Your check sheet should note the date you ran a search and the number of hits you found. You do not need to analyze each report in depth. You just need to show you looked and saw no pattern that would stop you from listing the substance. Print the search result summary page and add it to the file.

If you do see a cluster of serious reports, pause and get expert advice. A cluster is a signal you cannot ignore. Document the pause and the advice you got. If you decide to go ahead, write down the reasons that support your choice. This shows you weighed the risk and made a careful call. That is the core of what due diligence means in practice.

How a Category Change Affects Your Existing Stock

When a substance moves from category 2 to category 1, your stock does not become legal on its own. You must check that the batch you hold meets all the new conditions. The supplier must be registered and the substance must meet the right purity standards. If your stock was sourced for research use only, it may not meet the compounding bar. You cannot simply relabel a research vial as a compounding ingredient.

You also need to look at the date you got the stock. If you bought it before the effective date of the change, you must show it still meets the current specs. Get a fresh certificate of analysis if the old one is out of date. If the supplier cannot give you a new one, you may need to send a sample to a third party lab. The cost of the test is part of the cost of moving stock from one use class to another.

Segregate stock by legal status clearly

Your storage area should have a clear line between research stock and compounding stock. Use different colored bins or different shelf labels. The label should state the use class in large print. This stops a picker from grabbing the wrong vial by mistake. A mix up can lead to a serious compliance breach. The breach can cost you your license even if no product ships.

Your inventory software should also track the use class for each lot. Add a field that flags a lot as research only or compounding eligible. Run a report before each shift to check for lots that are close to the line. If a lot's status changes, update the software first, then move the physical stock. The digital record and the physical stock must match at all times.

Plan for stock you cannot convert

Some stock will not meet the compounding standard no matter what you do. You may have bought it from a supplier who is not registered with the FDA. Or the purity may fall short of the USP standard. In that case, you must keep it in the research only channel or dispose of it. You cannot donate it or sell it at a discount for compounding use. The law does not allow a gray market for subpar stock.

Work with a waste disposal firm that gives you a certificate of destruction. Keep that certificate in your records. It proves you did not let the stock slip into the wrong channel. If you write off the cost, talk to your tax advisor about how to book the loss. The loss is a real cost of doing business in a field with shifting rules. Plan for it in your annual budget.

Payment Processing Rules for Compounded Peptide Sales

Payment processors treat compounded drug sales as a high risk category. You must tell your processor exactly what you sell. If you hide the fact that you sell compounded peptides, they can freeze your account. A freeze can lock your cash for weeks or months. Be upfront from the first call. Give them your FDA registration number and your state license details.

You may need a processor that works with pharmacy accounts. Not all processors will touch this space. Ask if they have an active pharmacy portfolio. Ask what documents they need for underwriting. You will likely need to show your standard operating procedures and your compliance records. The more you can show that you run a tight ship, the better your rate will be.

Prepare a one page business brief for underwriting

Underwriters do not have time to read a fifty page manual. Give them a one page brief that sums up your business. List your licenses, your compounder type, and the substance categories you handle. State that you only sell to licensed practitioners or state licensed pharmacies, if that is true. Add a short paragraph on your quality checks. Keep the tone factual and calm.

Attach copies of your key documents to the brief. Include your state license, your FDA registration, and a sample certificate of analysis. This lets the underwriter check the boxes fast. A fast review means you get approved sooner. Update the brief once a year or when a key fact changes. Send the new version to your processor so they always have current data on file.

Watch for chargeback triggers unique to this space

Chargebacks can spike if your product description is not clear. A buyer may expect a ready to use product and get a bulk ingredient instead. Your checkout page must state plainly what the buyer will get. Use simple words like "bulk powder for compounding" or "research peptide, not for human use." A clear statement cuts down on disputes.

Also track the average time from order to door. Delays can lead to chargebacks. If a batch is stuck in quality testing, tell the buyer before they ask. A short email with a new ship date keeps trust high. Keep a log of all buyer contacts about delays. If a chargeback does come, you can show the log to the processor. This proof can help you win the dispute.

Shipping Compounded Peptides Across State Lines

Shipping compounded peptides to another state adds a layer of rules. You must follow the rules of both the state you ship from and the state you ship to. The receiving state may require a license or a registration even if you never set foot there. Some states treat an incoming shipment as the practice of pharmacy in their state. You must check the receiving state's pharmacy practice act before you send the first package.

Temperature control is also a key part of shipping. Many peptides break down if they get too warm. You need a cold chain plan that keeps the product in the right range from your door to the buyer's door. Use insulated boxes and cold packs that are tested for the full transit time. Include a temperature monitor in the box for high value shipments. The monitor gives you and the buyer a clear record of the trip.

Map each state's non resident pharmacy rules

Most states have a non resident pharmacy license that you must hold to ship into their borders. The application asks for your home state license, a list of your officers, and a copy of your inspection report. Some states also want a copy of your policies on storage and shipping. The fee and the wait time vary a lot from state to state. Start the process early for any state you plan to serve.

Keep a spreadsheet with the license number, the issue date, and the renewal date for each state. Set alerts for the renewal windows so you do not let a license lapse. A lapsed license can stop your shipments cold. If a state changes its rules, update the spreadsheet and brief your team. Your shipping software should block orders to any state where your license is not current.

Set clear delivery windows and signature rules

Your checkout page should show a realistic delivery window for each state. Do not promise next day delivery if the cold chain check takes two days. A late package can lead to a spoiled product and an angry buyer. Build in a buffer for weather delays and carrier errors. A happy buyer is one who gets the package when you said they would.

Require an adult signature on delivery for all compounded peptide shipments. This keeps the package from sitting on a hot porch. It also gives you a record of who took the box. If a buyer says a package never came, you can pull the signature. This small step protects both you and the buyer. It costs a bit more but it is worth the peace of mind.

How a Substance Gets Added to the Category 2 List

A substance does not land on the Category 2 list by accident. The FDA builds the list from public nominations. A group or a person sends a name to the agency. The agency then asks its Pharmacy Compounding Advisory Committee to look at the data. The committee checks if the substance is safe to compound. It also checks if there is a real need for it. The group votes on a path forward. The FDA takes that vote and makes a final call. The whole process can take many months. You can track the steps on the FDA advisory committee page.

The list is not frozen in place. The FDA can add new names or remove old ones. A removal often starts when new safety data comes to light. The agency may also act if a drug maker gets a new approved product. When that happens, the bulk form may no longer be needed. The FDA then moves the substance to a different category. You should check the list often. A change can shift what you may sell overnight. The bulk drug substances used in compounding page is the best place to watch for updates.

The nomination and public comment window

Anyone can send a nomination to the FDA. Most come from drug makers or pharmacy groups. The nomination must show why the substance is needed. It must also show that the raw form can be made safely. The FDA posts the nomination for the public to see. Then a comment window opens for at least 60 days. During that time, any person can send a note to the agency. The note can support the nomination or push back on it. The FDA reads every comment before it acts.

The comment window is your chance to speak up. If a substance you sell is under review, you can send data. You can share lab tests that show the raw form is stable. You can also share records that show a clean supply chain. Your input can help the committee see the full picture. If you stay quiet, the agency only sees what the nominator sent. A well timed comment can keep a key product on the market. Set a reminder to check the FDA docket every month.

The advisory committee vote and final placement

The Pharmacy Compounding Advisory Committee holds a public meeting. At the meeting, the group looks at the safety data for each substance. They also look at the clinical need. Then they vote. A vote to place a substance on the Category 2 list means the group sees real risk. The FDA almost always follows the vote. The final placement gets published in the Federal Register. From that date, the new status takes effect. You can watch past meetings on the Pharmacy Compounding Advisory Committee page.

A vote is not the end of the road. The FDA can revisit a placement if new facts come up. A drug maker can run a new study and send it to the agency. A pharmacy group can ask for a new hearing. The key is to have strong data. Anecdotes and short term sales trends do not move the needle. Lab data and peer reviewed papers do. If you want to protect a substance you sell, build a file of solid proof. Keep that file ready in case the agency opens a new review.

Supply Chain Paperwork for Category 2 Substances

When you sell a Category 2 substance, your paperwork must be clean. The FDA looks at the whole chain from the raw maker to the final seller. You need to show that every step was tracked. A certificate of analysis is the core document. It tells you what is in the batch and how pure it is. You must get one from your supplier for every lot you buy. Keep these on file for at least two years. If the FDA asks, you must hand them over fast. A missing certificate can end your ability to sell that product.

You also need to check the supplier itself. Ask for a site visit report or a third party audit. The supplier should follow good manufacturing practices. If they do not, your risk goes up. The FDA can hold you responsible even if the fault is upstream. A supplier with a history of warning letters is a red flag. You can look up past FDA actions on the agency website. A clean supply chain is not just good practice. It is your first line of defense if a batch is ever questioned. The certain bulk drug substances that may present significant safety risks page shows what the agency flags.

Reading a certificate of analysis like a pro

A certificate of analysis has many lines of data. You do not need to be a chemist to read the key parts. First, look at the lot number. It must match the lot on your bottle. Next, look at the purity number. It is often a percent like ninety nine point five. If the number is below the standard set by the FDA, do not accept the batch. Also check the date of the test. A certificate that is more than two years old may not be valid. The substance can change over time even in a sealed container.

Look for the test method used. A good certificate names the method, such as HPLC or mass spec. If the method is missing, ask your supplier why. A vague certificate is a warning sign. You should also check for heavy metal and microbe tests. These show the substance is free of harmful bits. If any test is absent, the certificate is not complete. A complete certificate protects you. It shows you did your job to check the batch before you sold it.

Building a supplier qualification file

You should keep a file on every supplier you use. The file should hold their license and their last audit report. If they have an FDA registration number, put that in the file too. Add a copy of their standard operating procedure for quality checks. If they ever send you a batch that fails a test, note that in the file. A pattern of failed batches is a reason to switch suppliers. The file shows the FDA that you pick partners with care. It is not enough to buy from the cheapest source.

Update the file once a year. Send a short email to each supplier asking for any new licenses or audit results. If a supplier does not reply, that is a problem. A good supplier will share updates without a fight. If a supplier pushes back, they may be hiding something. Your file is your proof that you acted in good faith. In a world where the rules shift often, good faith is your best shield. The compounding laws and policies page lays out the baseline you must meet.

Payment Processing and Banking Rules for Peptide Sellers

Banks treat peptide sales as a high risk business. Even if your products are legal, a bank can freeze your account. They do this to protect themselves from fines. You must be open with your bank from day one. Tell them what you sell and show them your compliance file. If you hide your product type, the bank will find out. When they do, they will likely close your account with no warning. A sudden freeze can kill your cash flow overnight. You need a bank that knows your business and agrees to work with you.

Payment processors have their own rules. Stripe and PayPal often block peptide sales. You may need a high risk processor that knows the field. These processors charge higher fees, often five to eight percent per sale. They may also hold a rolling reserve of your funds for up to six months. This is normal for the space. Plan your cash flow around these holds. A processor that understands research products will ask for your lab certificates and your terms of sale. Have those ready before you apply. The meaning of intended uses page helps you write terms that keep you in the research use lane.

Writing a compliant sales terms page

Your sales terms page is a legal shield. It must state clearly that your products are for research use only. It must say that the buyer agrees not to use them on people or animals. It must also say that the buyer takes full responsibility for following local laws. A strong terms page can help you keep your payment accounts open. The processor will read it before they approve your account. If the terms are vague, they will deny you. Write in short, plain words that a sixth grader can follow.

Add a clause about age. The buyer must be at least twenty one years old. Add a clause about export rules. The buyer must not ship the product to a place where it is banned. Keep a log of every time a buyer checks the box to agree. That log is your proof that the buyer knew the rules. If a buyer ever breaks the terms, you can point to the log. It shows you did not intend for the product to be misused. Intent is the key word in the FDA rules.

Keeping a reserve fund for account freezes

Even with a good bank, freezes happen. A bank may flag a single transaction and lock your whole account. It can take weeks to get the funds released. You need a backup plan. Keep at least one month of operating cash in a separate bank. That bank should not be linked to your sales account. If your main account freezes, you can still pay your suppliers and your staff. A reserve fund is not a nice to have. It is a core part of running a peptide business.

Also keep a file of your last three months of bank statements. If you need to open a new account fast, those statements will help. A new bank will want to see your sales volume and your chargeback rate. A low chargeback rate, under one percent, makes you look stable. If your rate is high, work on your customer service to bring it down. A stable banking record is worth as much as a clean lab certificate. Both keep your business alive when the rules shift.

Next Steps

Review the FDA's compounding pages directly. Read the "Certain Bulk Drug Substances that May Present Significant Safety Risks" page and the "Compounding Laws and Policies" page. Understand that the update is a narrow administrative change. Confirm that your product pages, support replies, and marketing materials stay on research use only facts. Do not add language about the FDA update that implies a new legal status for your products.

This article does not provide legal advice. A business owner should consult a business attorney who understands FDA law for the owner's own situation. The attorney can review the specific facts of the business and give an opinion based on current law.

For help building a research use only peptide brand that stays within its scope, Book Your Call.

Frequently Asked Questions

Are peptides legal again in 2026?

No. The FDA updated a compounding list to show that several peptide nominations were withdrawn. This is not a new approval or a change that makes peptides broadly legal to sell for use by people.

What did FDA change on its compounding pages?

The FDA moved AOD-9604, BPC-157, CJC-1295, Epitalon, Selank, Semax, Thymosin alpha 1, Thymosin Beta-4 Fragment, and other substances from category 2 to a withdrawn status on its safety risks page. The change reflects nominators pulling their submissions.

Does a withdrawal from category 2 mean FDA approval?

No. A withdrawal means the review process stopped. The FDA did not make a safety or effectiveness finding. The substances are not approved by the FDA for compounding or any other use.

What is the Pharmacy Compounding Advisory Committee?

The PCAC is an FDA advisory committee that reviews bulk drug substances nominated for compounding. It makes recommendations to the FDA. Its work does not govern research use only sales.

Does the compounding list cover research use only sellers?

No. The compounding lists apply to pharmacies and outsourcing facilities under sections 503A and 503B. A research use only seller is not a compounding pharmacy and is not governed by these lists.

Sources

• Primary source at www.fda.gov
• Primary source at www.fda.gov
• Primary source at www.fda.gov
• Primary source at www.fda.gov
• Primary source at www.law.cornell.edu